BBV154

BBV154
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Routes of
administration
Intranasal
ATC code
  • None

BBV154 is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech,[1][2] American company Precision Virologics[3][4] and the Washington University School of Medicine in St Louis, Missouri, United States.[5][6]

Clinical trials

Phase I trials

On recommendation by the Subject Expert Committee (SEC) under the Indian drug regulator, the company is going to conduct phase 1 clinical trials using 75 volunteers and submit safety and immunogenicity data for the committee’s consideration before it proceeds to the second phase of the trial.[7]

Phase II and III trials

On 12 August 2021, after evaluating the results of phase I trial data, the drug regulator approved for phase II/III randomized trials that involves evaluation of the immunogenicity and safety of Covaxin with BBV154 in healthy volunteers.[8]

References

  1. ^ Clinical trial number NCT04751682 for "Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19" at ClinicalTrials.gov
  2. ^ "Intranasal Vaccine For Covid-19". Bharat Biotech. Retrieved 5 March 2021.
  3. ^ "St. Louis-based Precision Virologics and India's Biotech leader Bharat Biotech obtain rights to intranasal COVID-19 vaccine technology". www.biostl.org. Retrieved 29 August 2021.
  4. ^ Hassan, AO; Kafai, NM; Dmitriev, IP; Fox, JM; Smith, BK; Harvey, IB; Chen, RE; Winkler, ES; Wessel, AW; Case, JB; Kashentseva, E; McCune, BT; Bailey, AL; Zhao, H; VanBlargan, LA; Dai, YN; Ma, M; Adams, LJ; Shrihari, S; Danis, JE; Gralinski, LE; Hou, YJ; Schäfer, A; Kim, AS; Keeler, SP; Weiskopf, D; Baric, RS; Holtzman, MJ; Fremont, DH; Curiel, DT; Diamond, MS (1 October 2020). "A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2". Cell. 183 (1): 169–184.e13. doi:10.1016/j.cell.2020.08.026. PMC 7437481. PMID 32931734.
  5. ^ "Bharat Biotech to make a billion doses of an intranasal adenovirus vaccine". The Indian Express. 23 September 2020. Archived from the original on 3 May 2021. Retrieved 23 September 2020.
  6. ^ "Bharat Biotech Partners With US University For Covid Intranasal Vaccine". NDTV.com. Archived from the original on 3 May 2021. Retrieved 23 September 2020.
  7. ^ Raghavan P (30 January 2021). "Explained: Understanding BBV154, Bharat Biotech's single-dose intranasal Covid-19 vaccine". The Indian Express.
  8. ^ Gaurav, Kunal (13 August 2021). "First nasal vaccine developed by Bharat Biotech gets nod for Phase 2/3 trial". Hindustan Times.

External links

Media files used on this page

Coronavirus. SARS-CoV-2.png
Author/Creator: Alexey Solodovnikov (Idea, Producer, CG, Editor), Valeria Arkhipova (Scientific Сonsultant), Licence: CC BY-SA 4.0
Scientifically accurate atomic model of the external structure of the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), a strain (genetic variant) of the coronavirus that caused Coronavirus disease (COVID-19), first identified in Wuhan, China, during December 2019

Each separate locus (amorphous blob) is an atom of:

  cobalt: membrane
  crimson: E protein
  green: M protein
  orange: glucose (glycan)
  turquoise : S (spike) glycoprotein
SARS-CoV-2 (Wikimedia colors).svg
Author/Creator: Geraki, Licence: CC BY-SA 4.0
SARS-CoV-2 logo in Wikimedia colors
Scholia logo.svg
Author/Creator: Lars Willighagen, Licence: CC BY-SA 4.0
SVG remake of proposal for Scholia logo (File:Scholia logo.png by User:Theklan).
WHO Rod.svg
The rod of Asclepius as depicted in the WHO logo.
Sida-aids.png
Author/Creator: User:FoeNyx © 2004 (artistic illustration), Licence: CC-BY-SA-3.0
VIH - HIV / SIDA - AIDS viruses.
SARS-CoV-2 (CDC-23312).png
This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by the 2019 Novel Coronavirus (2019-nCoV). Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically. This virus was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.
Syringe with Green Fluid.jpg
Author/Creator: Andres Rueda, Licence: CC BY 2.0
The following is the author's description of the photograph quoted directly from the photograph's Flickr page.
"Just wanted to test something with my ink refiller syringe. Filled with a oral-b mouthwash to give the greenish-blueish Max Payne valkyr effect. "